Detalhe da pesquisa
1.
Acalabrutinib, venetoclax and obinutuzumab in relapsed CLL: Final efficacy and ctDNA analysis of the CLL2-BAAG trial.
Blood
; 2024 Apr 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-38620072
2.
Reassessing the Chronic Lymphocytic Leukemia International Prognostic Index in the era of targeted therapies.
Blood
; 2024 Apr 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-38620092
3.
Final analysis of the CLL2-GIVe trial: obinutuzumab, ibrutinib, and venetoclax for untreated CLL with del(17p)/TP53mut.
Blood
; 142(11): 961-972, 2023 09 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-37363867
4.
The CLL12 trial: ibrutinib vs placebo in treatment-naïve, early-stage chronic lymphocytic leukemia.
Blood
; 139(2): 177-187, 2022 01 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-34758069
5.
High-risk stays high-risk: Bruton tyrosine kinase inhibitors in B-cell malignancies.
Haematologica
; 2024 Mar 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-38450529
6.
Chronic Lymphocytic Leukemia: Time-Limited Therapy in the First-Line Setting and Role of Minimal Residual Disease.
Curr Oncol Rep
; 26(2): 136-146, 2024 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-38175465
7.
Importance of Minimal Residual Disease in the Era of Targeted Therapies in Chronic Lymphocytic Leukemia.
Acta Haematol
; 147(1): 22-32, 2024.
Artigo
em Inglês
| MEDLINE | ID: mdl-37903476
8.
Durable remissions following combined targeted therapy in patients with CLL harboring TP53 deletions and/or mutations.
Blood
; 138(19): 1805-1816, 2021 11 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34086865
9.
Pirtobrutinib versus venetoclax in covalent Bruton tyrosine kinase inhibitor-pretreated chronic lymphocytic leukemia: a matching-adjusted indirect comparison.
Haematologica
; 2023 Nov 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-38031799
10.
Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions.
N Engl J Med
; 380(23): 2225-2236, 2019 Jun 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-31166681
11.
Prognostic and predictive impact of genetic markers in patients with CLL treated with obinutuzumab and venetoclax.
Blood
; 135(26): 2402-2412, 2020 06 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-32206772
12.
The role of minimal residual disease in chronic lymphocytic leukemia.
Clin Adv Hematol Oncol
; 20(2): 97-103, 2022 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-35120090
13.
Bendamustine, followed by ofatumumab and ibrutinib in chronic lymphocytic leukemia (CLL2-BIO): primary endpoint analysis of a multicenter, open-label phase-II trial.
Haematologica
; 106(2): 543-554, 2021 02 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32107341
14.
Chronic lymphocytic leukemia: 2022 update on diagnostic and therapeutic procedures.
Am J Hematol
; 96(12): 1679-1705, 2021 12 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34625994
15.
Health-related quality of life with fixed-duration venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: Results from the randomized, phase 3 CLL14 trial.
Am J Hematol
; 96(9): 1112-1119, 2021 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34050972
16.
Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial.
Lancet Oncol
; 21(9): 1188-1200, 2020 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-32888452
17.
[Chronic lymphocytic leukemia]. / Chronische lymphatische Leukämie.
Internist (Berl)
; 61(3): 277-287, 2020 Mar.
Artigo
em Alemão
| MEDLINE | ID: mdl-32047946
18.
Mode of progression after first line treatment correlates with outcome of chronic lymphocytic leukemia (CLL).
Am J Hematol
; 94(9): 1002-1006, 2019 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-31222797
19.
Infections in patients with chronic lymphocytic leukemia treated with time limited targeted drug combinations.
Am J Hematol
; 2024 May 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-38757754
20.
Bendamustine, followed by obinutuzumab and idelalisib in chronic lymphocytic leukemia (CLL2-BCG): Final analysis of a multicenter, open-label phase-II-trial.
Am J Hematol
; 99(6): 1192-1195, 2024 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-38578022